Search results for: 'distributed drug of service dosag'

Small molecules, which are the leading drug class across indications, face several issues that threaten their drug delivery efficacy. They suffer from off-target effects, poor bioavailability, low solubility, systemic toxicity, and poor permeability. While the small molecule drug development pipeline remains a leading therapeutic class, it is essen...

Frost & Sullivan’s analysis of the oral solid dosage excipients market aims at quantifying the consumption and analyzing the impact of key disruptive, transformative, and competitive trends across the value chain order to present a forecast for the eight year period of 2022 to 2030. The scope of the study comprises analysis of the oral solid dosage...

The distribution infrastructure and delivery sector is undergoing a profound transformation, driven by the explosive growth of digital content consumption, the proliferation of edge computing, and the relentless evolution of security threats in an increasingly interconnected world. The focus in this sector has shifted from simply moving data effici...

Excipients have been a part of the pharmaceutical industry and their demand is expected to increase during the forecast period. This is owing to their ability to perform various functions such as improving the stability of the active pharmaceutical ingredient (API), modifying drug release, and masking taste. Expanding patient base coupled with the ...

This study examines the global distribution transformer market, analyzing demand drivers, technological trends, and competitive dynamics across key regions. It explores how rising electricity consumption, grid modernization programs, and the integration of distributed energy resources are reshaping replacement and new‑build requirements for distrib...

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....

The discovery of new drug targets for diseases with unmet medical needs has long been hindered by the complexity of processing and interpreting massive volumes of biological data. The increasing volume and veracity of clinical and research data compels the use of enabling tools and technologies, such as cloud computing, AI, machine learning, natura...

For a long time, drug discovery followed the same path and used conventional analysis methods for proposed targets. Today, changes in technology and the ability to study omics are transforming drug development. Personalized therapy is on the rise and promises to be more effective and efficient in addressing challenges. With growing interest in ...

The SynBio field has evolved well over the past two decades, with significant technology disruptions leading to new opportunities and remarkable growth potential. Advances in SynBio technologies have transformed drug discovery and therapeutics development, accelerating the identification of novel drug targets and high-throughput compound screening ...